Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM versus DIATRIZOATE 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM versus DIATRIZOATE 60.
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM vs DIATRIZOATE-60
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Radiopaque contrast agent that attenuates X-rays, providing visualization of vascular and urinary structures. It is a high-osmolality ionic dimer that distributes in extracellular fluid and is excreted renally.
Diatrizoate is an ionic, monomeric, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, enhancing radiographic imaging by attenuating X-ray beams. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Intravascular administration for angiography (cerebral, coronary, peripheral), venography, and digital subtraction angiographyOral or rectal administration for gastrointestinal tract imagingIntravenous urographyOff-label use: CT imaging enhancement
Radiographic contrast agent for angiography, urography, computed tomography (CT), and other imaging proceduresOff-label: direct injection for fistulography, arthrography, and hysterosalpingography
Intra-arterial or intravenous administration; adult dose varies by procedure: for intravenous urography, 50-100 mL of 60% solution; for CT enhancement, 100-150 mL of 60% solution; maximum total dose 4.2 g iodine/kg body weight.
1-2 mL/kg IV bolus up to 150 mL total for contrast-enhanced CT; repeat doses may be given based on imaging needs.
None Documented
None Documented
1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe impairment)
Terminal half-life approximately 1-2 hours in patients with normal renal function. Prolonged in renal impairment (up to 20-30 hours in anuria).
Not metabolized; excreted unchanged by glomerular filtration.
Not metabolized; excreted unchanged by the kidneys via glomerular filtration.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Negligible biliary or fecal elimination.
~10% bound to plasma proteins (albumin)
Very low; less than 5% bound, primarily to albumin.
0.2-0.3 L/kg; primarily extracellular
Approximately 0.2-0.3 L/kg, confined to extracellular fluid; no significant tissue penetration.
Oral: <5%; rectal: ~30%
Bioavailability is 100% for intravenous and intra-arterial routes; oral bioavailability near 0% (not absorbed).
Contraindicated in anuria or severe renal impairment (eGFR <30 mL/min/1.73 m²); for moderate impairment (eGFR 30-59 mL/min/1.73 m²), use with caution, ensure adequate hydration, and consider lowest diagnostic dose.
eGFR >60 mL/min: no adjustment. eGFR 30-60: reduce dose by 50% or use alternative if possible. eGFR <30: avoid use; if essential, use minimum dose (0.5 mL/kg) with pre-hydration and N-acetylcysteine.
No specific dose adjustment for hepatic impairment; use caution in severe hepatic disease due to potential for adverse effects.
No specific dose adjustment for Child-Pugh class; use cautiously in severe hepatic impairment due to risk of nephrotoxicity.
Weight-based: 0.5-2 mL/kg of 60% solution for intravenous urography or CT; maximum 4.2 g iodine/kg body weight.
0.5-2 mL/kg IV based on imaging protocol; maximum 150 mL. Adjust for weight: infants: 1-2 mL/kg, children: 1-1.5 mL/kg.
Elderly patients may have reduced renal function; assess renal function before administration and use lowest effective dose; ensure adequate hydration.
Lower initial doses (0.5-1 mL/kg) with careful monitoring of renal function; avoid in eGFR <30 mL/min.
Not recommended for intrathecal use; severe adverse reactions including death have occurred.
Not recommended for intrathecal use; severe neurological complications including seizures, paralysis, and death can occur if administered into the subarachnoid space.
Risk of contrast-induced nephropathy, especially in patients with pre-existing renal impairment, diabetes, dehydration. Hypersensitivity/anaphylactoid reactions possible. Severe cardiovascular reactions including arrhythmias, hypotension, cardiac arrest. Thyroid storm in patients with hyperthyroidism. Sickle cell disease patients may experience vaso-occlusive crises.
["Risk of acute kidney injury (AKI) in patients with pre-existing renal impairment, diabetes, or dehydration","Anaphylactoid reactions, including hypotension, bronchospasm, and angioedema","Contrast-induced nephropathy (CIN)","Hypersensitivity reactions"]
Absolute: History of hypersensitivity reaction to diatrizoate; intrathecal administration. Relative: Anuria or severe renal impairment; concurrent use of metformin in patients with renal impairment; multiple myeloma; pheochromocytoma; hyperthyroidism; pregnancy.
["Known hypersensitivity to diatrizoate or any component","Intrathecal administration (absolute)","Severe renal impairment (relative, use with caution)"]
Data Pending Review
Data Pending Review
No specific food interactions. However, patients with diabetes should follow blood glucose monitoring instructions, especially if metformin is temporarily withheld.
No specific food interactions are known. However, patients should maintain adequate hydration with clear fluids before and after contrast administration. Fasting for blood tests may be required prior to the procedure, but this is not a drug-food interaction per se.
Diatrizoate is an ionic iodinated contrast agent. Animal studies have not shown teratogenic effects. In humans, therapeutic doses during pregnancy are considered low risk, but elective use should be avoided. First trimester: theoretical risk of fetal hypothyroidism from free iodide; second and third trimesters: minimal risk with standard doses. No malformations attributed to diatrizoate.
Diatrizoate is an iodinated contrast agent. There is no evidence of teratogenicity in humans based on limited data; however, as a precaution, avoid use in the first trimester when organogenesis occurs. Inadvertent exposure during pregnancy has not been associated with an increased risk of major birth defects. Use only if clearly needed and risk-benefit justifies exposure.
Diatrizoate is excreted into breast milk in minimal amounts, with an M/P ratio of approximately 0.1. Oral bioavailability in infants is low (<1%). The American College of Radiology considers it compatible with breastfeeding; no interruption required.
Diatrizoate is excreted into breast milk in very low quantities (<0.01% of maternal dose). The M/P ratio is not well defined but is low. The American College of Radiology suggests no special precautions are needed, and breastfeeding can be continued normally after contrast exposure.
No pharmacokinetic changes necessitating dose adjustment in pregnancy. Use lowest dose sufficient for diagnostic imaging. Contraindicated in patients with known hypersensitivity to iodinated contrast.
No specific dose adjustments are recommended for pregnancy, but the lowest possible dose should be used to achieve diagnostic imaging. Standard adult dosing applies; however, consider the altered volume of distribution and increased renal clearance in pregnancy, which may affect contrast elimination but not require dose modification.
Category C
Category C
Diatrizoate meglumine and diatrizoate sodium is an ionic, high-osmolar iodinated contrast agent (HOCM) used for radiographic imaging. Risk of contrast-induced nephropathy (CIN) is highest in patients with pre-existing renal impairment (eGFR <30 mL/min), diabetes, or volume depletion. Pre-hydration with isotonic saline (1 mL/kg/hr for 12 hours pre- and post-procedure) reduces CIN risk. Avoid concurrent use of nephrotoxic drugs (e.g., NSAIDs, metformin). Have resuscitation equipment available due to risk of anaphylactoid reactions, especially in patients with asthma or prior contrast reactions. For patients with a history of moderate-to-severe allergic reaction, premedication with corticosteroids (e.g., prednisone 50 mg PO at 13, 7, and 1 hour before) and diphenhydramine (50 mg IV/PO) is recommended. Extravasation can cause tissue necrosis; treat with elevation, cold compresses, and close monitoring.
Diatrizoate-60 (Hypaque-60) is a high-osmolar ionic monomer contrast agent used for angiocardiography, excretory urography, and CT enhancement. Pre-hydration with IV fluids reduces risk of contrast-induced nephropathy (CIN) especially in patients with CKD, diabetes, or age >70. Assess renal function (eGFR) prior to administration; consider N-acetylcysteine or sodium bicarbonate protocol in high-risk patients. Risk of delayed hypersensitivity reaction (e.g., rash, fever) up to 72 hours post-injection, especially in patients with prior contrast allergy. Have emergency equipment available for anaphylaxis. In patients with multiple myeloma, dehydration increases risk of renal failure; ensure adequate hydration. Intrathecal administration is contraindicated (use low-osmolar nonionic agents).
Drink plenty of water before and after the procedure unless told otherwise by your doctor.Inform your doctor if you have any allergies, especially to contrast agents or iodine.Tell your healthcare team if you have kidney disease, diabetes, asthma, or are pregnant.You may feel a warm flush or metallic taste when the contrast is injected; this is normal.Notify a nurse immediately if you experience difficulty breathing, hives, or swelling of the face or throat.If you take metformin, your doctor may ask you to stop it temporarily to prevent lactic acidosis.
You may experience a warm sensation, metallic taste, or flushing during the injection; this is temporary.Drink plenty of water before and after the procedure to help protect your kidneys unless instructed otherwise by your doctor.Notify your doctor immediately if you develop hives, itching, difficulty breathing, or swelling after the procedure.Inform your healthcare providers if you have a history of allergic reactions to contrast dye, asthma, or kidney disease.If you are diabetic and taking metformin, your doctor may ask you to stop it temporarily to prevent a rare complication called lactic acidosis.Mild side effects like nausea or headache may occur; report severe or persistent symptoms.